Developing a next-generation therapeutic pipeline

Our mission is to bring transformative pain management solutions to patients suffering from acute, chronic, and neuropathic pain.

Our pipeline of next-generation therapeutics focuses on using novel science to generate unrivaled clinical outcomes. Every step of the way, we work closely with global regulatory agencies to ensure that the safety, efficacy and quality of our pain medications meet – and ideally exceed – standards.

Product Indication Preclinical IND Phase 1 Phase 2 Phase 3/Pivotal NDA
CebranopadolTRN-228
Acute pain
Chronic low back pain
Chronic neuropathic pain
Substance use disorder
Adneuris Pipeline — TRN-228 (Cebranopadol)
Cebranopadol TRN-228
Acute pain
Preclinical IND Phase 1 Phase 2 Phase 3/Pivotal NDA
Phase 3 / Pivotal
Chronic low back pain
Preclinical IND Phase 1 Phase 2 Phase 3/Pivotal NDA
Phase 2
Chronic neuropathic pain
Preclinical IND Phase 1 Phase 2 Phase 3/Pivotal NDA
Phase 2
Substance use disorder
Preclinical IND Phase 1 Phase 2 Phase 3/Pivotal NDA
IND

Phase 3

Cebranopadol: Phase 3 completed for acute pain; Phase 3 studies planned for chronic pain

The first and only investigational dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor (dual-NMR) agonist for the treatment of pain.

Cebranopadol offers a unique approach to pain biology modulation through its first-in-class mechanism: the dual-NMR agonist. Its profile has been well-characterized in more than 33 efficacy and safety clinical trials involving approximately 2,200 adults to date. Data from these studies show cebranopadol:

  • has the potential to treat acute, chronic and neuropathic pain effectively.1-5
  • has a reduced potential for the detrimental side effects associated with conventional opioids such as physical dependence and misuse​.6-8
  • may have significantly lower risk of respiratory depression than conventional opioids.9
  • is well-tolerated and its proposed simple, once-a-day dosing that may not require adjustment for food, renal or hepatic impairment, or tapering at the end of therapy.1,2,8

Because of its unique mechanism of action, cebranopadol has the potential to significantly change the pain-relief landscape. Notably, the FDA has granted Fast Track Designation to cebranopadol for chronic low back pain. If approved, this investigational therapy could become the first and only dual-NMR agonist for the treatment of pain with significantly less potential for misuse or risk of physical dependence, addiction or overdose than conventional opioids.

References:

  1. Singla N, Minkowitz H, Vaughn B, Grieco J, Lesnick M, Hackworth J. Results of a randomized, placebo-controlled, Phase 3 trial of cebranopadol for the treatment of acute pain after abdominoplasty. Presented at: The: American Society of Regional Anesthesia (ASRA); May 2025. 
  2. Data on file. Tris Pharma, Inc. 2025.
  3. Christoph A, Eerdekens MH, Kok M, Volkers G, Freynhagen R. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain. 2017 Sep;158(9):1813-1824. 
  4. Eerdekens MH, Kapanadze S, Koch ED, et al. Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial. EurJ Pain. 2019;23(3):577-588.
  5. Eerdekens M, Koch ED, Kok M, Sohns M, Forst T. Cebranopadol, a novel first in class analgesic: efficacy safety and tolerability in patients with pain due to diabetic peripheral neuropathy (DPN). Presented at the World Institute of Pain; May 2016.
  6. Apseloff G, Pardo A, Shram M, Grieco JC, Lesnick ML, Hackworth JC. Limited oral abuse potential of cebranopadol, a novel potent analgesic, compared to tramadol and oxycodone in recreational opioid users. Presented at: PainWeek; September 2023. 
  7. Shram M, Apseloff G, Grieco J, Fam D, Lesnick M, Hackworth J. Abuse potential assessment of eebranopadol, a novel dual nociceptin (NOP) and Mu opioid (MOP) receptor (NMR) agonist: Implications for scheduling. Presented at: The College on Problems of Drug Dependence; June 2025. 
  8. Fam D, Pardo A, Hackworth J. Cebranopadol, a novel potent analgesic: Pooled analysis of clinical opiate withdrawal sScales. Presented at: PainWeek; September 2022.
  9. Jansen S, Olofsen E, Moss L, et al. Respiratory and antinociceptive effects of a dual NOP-MOP receptor agonist cebranopadol versus full opioid receptor agonist oxycodone: a comparison in healthy volunteers. Anesthesiology. Published online December 11, 2025. doi:10.1097/ALN.0000000000005894
Neuron image: Dual-NMR agonism - A novel approach to treating pain and addiction.
Neuron image: Dual-NMR agonism - A novel approach to treating pain and addiction.